IL-4 and IL-10 Are Both Required for the Induction of Oral Tolerance
Overview
Affiliations
Protection from the development of experimental autoimmune uveitis (EAU) can be induced by feeding mice interphotoreceptor retinoid binding protein before uveitogenic challenge with the same protein. Two different regimens are equally effective in inducing protective tolerance, although they seem to do so through different mechanisms: one involving regulatory cytokines (IL-4, IL-10, and TGF-beta), and the other with minimal involvement of cytokines. Here we studied the importance of IL-4 and IL-10 for the development of oral tolerance using mice genetically engineered to lack either one or both of these cytokines. In these animals we were able to protect against EAU only through the regimen inducing cytokine-independent tolerance. When these animals were fed a regimen that in the wild-type animal is thought to predominantly induce regulatory cells and is associated with cytokine secretion, they were not protected from EAU. Interestingly, both regimens were associated with reduced IL-2 production and proliferation in response to interphotoreceptor retinoid binding protein. These findings indicate that both IL-4 and IL-10 are required for induction of protective oral tolerance dependent on regulatory cytokines, and that one cytokine cannot substitute for the other in this process. These data also underscore the fact that oral tolerance, manifested as suppression of proliferation and IL-2 production, is not synonymous with protection from disease.
Oral tolerance as antigen-specific immunotherapy.
Pinheiro-Rosa N, Torres L, Oliveira M, Andrade-Oliveira M, Guimaraes M, Coelho M Immunother Adv. 2022; 1(1):ltab017.
PMID: 35919733 PMC: 9327124. DOI: 10.1093/immadv/ltab017.
Research Progress on the Mechanism of Natural Product Ingredients in the Treatment of Uveitis.
Li S, Liu F, Zhang K, Tong Y, Liu X J Immunol Res. 2021; 2021:6683411.
PMID: 34778467 PMC: 8585548. DOI: 10.1155/2021/6683411.
Sun Y, Guo D, Liu B, Yin X, Wei H, Tang K Mediators Inflamm. 2018; 2018:2574067.
PMID: 30510488 PMC: 6231386. DOI: 10.1155/2018/2574067.
Weinstein J, Pepple K Curr Opin Ophthalmol. 2018; 29(3):267-274.
PMID: 29521875 PMC: 7199509. DOI: 10.1097/ICU.0000000000000466.
Buerth C, Mausberg A, Heininger M, Hartung H, Kieseier B, Ernst J PLoS One. 2016; 11(5):e0155082.
PMID: 27159446 PMC: 4861260. DOI: 10.1371/journal.pone.0155082.